Last10K.com

Bellerophon Therapeutics, Inc. (BLPH) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, December 31, 2022

Bellerophon Therapeutics, Inc.

HISTORY TOOLS
CIK: 1600132 Ticker: BLPH
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Mar. 30, 2023
Jun. 30, 2022
Document and Entity Information   
Document Type10-K  
Document Annual Reporttrue  
Document Transition Reportfalse  
Document Period End DateDec. 31, 2022  
Entity File Number001-36845  
Entity Registrant NameBellerophon Therapeutics, Inc.  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number47-3116175  
Entity Address, Address Line One184 Liberty Corner Road  
Entity Address, Address Line TwoSuite 302  
Entity Address, City or TownWarren  
Entity Address, State or ProvinceNJ  
Entity Address, Postal Zip Code07059  
City Area Code908  
Local Phone Number574-4770  
Title of 12(b) SecurityCommon Stock, $0.01 par value per share  
Trading SymbolBLPH  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagfalse  
Entity Shell Companyfalse  
Entity Central Index Key0001600132  
Current Fiscal Year End Date--12-31  
Document Fiscal Year Focus2022  
Document Fiscal Period FocusFY  
Amendment Flagfalse  
Entity Public Float  $ 8.8
Entity Common Stock, Shares Outstanding 10,448,185 
Auditor Firm ID185  
Auditor NameKPMG LLP  
Auditor LocationShort Hills, New Jersey  

View differences made from one year to another to evaluate Bellerophon Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bellerophon Therapeutics, Inc..

Continue

Assess how Bellerophon Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Shares
Product
Geography
Dividend
Other
Inside Bellerophon Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Operations And Comprehensive Loss
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Commitments And Contingencies - Operating Lease Obligations (Details)
Common Stock Warrants
Common Stock Warrants (Details)
Common Stock Warrants (Tables)
Common Stock Warrants - Warrant Activity (Details)
Fair Value Measurements
Fair Value Measurements (Details)
Fair Value Measurements (Tables)
Fair Value Measurements - Weighted Average Assumptions (Details)
Income Taxes
Income Taxes (Details)
Income Taxes (Tables)
Income Taxes - Deferred Tax Assets And Liabilities (Details)
Income Taxes - Reconciliation Of Statutory Federal Income Tax Rate (Details)
Liquidity And Going Concern
Liquidity And Going Concern (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Net Loss Per Share (Tables)
Net Loss Per Share - Antidilutive Securities (Details)
Organization And Nature Of The Business
Organization And Nature Of The Business (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Right Of Use Assets And Leases
Right Of Use Assets And Leases (Details)
Right Of Use Assets And Leases (Tables)
Right Of Use Assets And Leases - Rou Assets, Lease Liabilities And Maturities (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Ikaria Equity Incentive Plans (Details)
Stock-Based Compensation - Incentive Plans (Details)
Stock-Based Compensation - Stock-Based Compensation Expense, Net Of Estimated Forfeitures (Details)
Stock-Based Compensation - Summary Of Fair Value Of Options Issued (Details)
Stock-Based Compensation - Summary Of Option Activity (Details)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Bellerophon Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: BLPH
CIK: 1600132
Form Type: 10-K Annual Report
Accession Number: 0001558370-23-005200
Submitted to the SEC: Fri Mar 31 2023 8:30:34 AM EST
Accepted by the SEC: Fri Mar 31 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/blph/0001558370-23-005200.htm